Keith L. Lui

Keith joined DURECT in May 2020 and brings over 18 years of biopharma experience in roles spanning global and US strategy and marketing, market access and operations, sales, business development and analytics, PR/IR and patient advocacy. Over his career, Keith has become an expert at helping clinical stage companies transition to full commercialization. He has made significant contributions to the strategic planning and launches of new medicines including Imbruvica and Zelboraf, and new indication launches for therapies such as Avastin and Rituxan. Previously, Keith helped build the US corporate infrastructure, commercial function and launch strategy at Oncopeptides. Prior to that, he led early commercial strategy and launch readiness efforts at Prothena and Versartis, and led the launch of Imbruvica at Pharmacyclics. Keith also worked in multiple oncology marketing roles at Genentech and held roles in pharmaceutical sales and genomics research. He earned a BA in Integrative Biology from the University of California at Berkeley and an MBA, with distinction, from Vanderbilt University.